Literature DB >> 22895052

Rbf1 degron dysfunction enhances cellular DNA replication.

Nitin Raj1, Liang Zhang, Yiliang Wei, David N Arnosti, R William Henry.   

Abstract

The E2F family of transcription factors contributes to oncogenesis through activation of multiple genes involved in cellular proliferation, a process that is opposed by the Retinoblastoma tumor suppressor protein (RB). RB also increases E2F1 stability by inhibiting its proteasome-mediated degradation, but the consequences of this post-translational regulation of E2F1 remain unknown. To better understand the mechanism of E2F stabilization and its physiological relevance, we examined the streamlined Rbf1-dE2F1 network in Drosophila. During embryonic development, Rbf1 is insulated from ubiquitin-mediated turnover by the COP9 signalosome, a multi-protein complex that modulates E3 ubiquitin ligase activity. Here, we report that the COP9 signalosome also protects the Cullin4-E3 ligase that is responsible for dE2F1 proteasome-mediated destruction. This dual role of the COP9 signalosome may serve to buffer E2F levels, enhancing its turnover via Cul4 protection and its stabilization through protection of Rbf1. We further show that Rbf1-mediated stabilization of dE2F1 and repression of dE2F1 cell cycle-target genes are distinct properties. Removal of an evolutionarily conserved Rbf1 C terminal degron disabled Rbf1 repression without affecting dE2F1 stabilization. This mutant form of Rbf1 also enhanced G(1)-to-S phase progression when expressed in Rbf1-containing S2 embryonic cells, suggesting that such mutations may generate gain-of-function properties relevant to cellular transformation. Consistent with this idea, several studies have identified mutations in the homologous C terminal domains of RB and p130 in human cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22895052      PMCID: PMC3495815          DOI: 10.4161/cc.21665

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  66 in total

Review 1.  The E2F transcriptional network: old acquaintances with new faces.

Authors:  Desssislava K Dimova; Nicholas J Dyson
Journal:  Oncogene       Date:  2005-04-18       Impact factor: 9.867

Review 2.  E2F transcription factor is a target for the RB protein and the cyclin A protein.

Authors:  J R Nevins; S P Chellappan; M Mudryj; S Hiebert; S Devoto; J Horowitz; T Hunter; J Pines
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1991

3.  Increased levels of E2F-1-dependent DNA binding activity after UV- or gamma-irradiation.

Authors:  M Höfferer; C Wirbelauer; B Humar; W Krek
Journal:  Nucleic Acids Res       Date:  1999-01-15       Impact factor: 16.971

4.  Retinoblastoma protein represses transcription by recruiting a histone deacetylase.

Authors:  L Magnaghi-Jaulin; R Groisman; I Naguibneva; P Robin; S Lorain; J P Le Villain; F Troalen; D Trouche; A Harel-Bellan
Journal:  Nature       Date:  1998-02-05       Impact factor: 49.962

5.  Phosphorylation- and Skp1-independent in vitro ubiquitination of E2F1 by multiple ROC-cullin ligases.

Authors:  T Ohta; Y Xiong
Journal:  Cancer Res       Date:  2001-02-15       Impact factor: 12.701

6.  Differential regulation of E2F transactivation by cyclin/cdk2 complexes.

Authors:  B D Dynlacht; O Flores; J A Lees; E Harlow
Journal:  Genes Dev       Date:  1994-08-01       Impact factor: 11.361

7.  Regulation of retinoblastoma protein functions by ectopic expression of human cyclins.

Authors:  P W Hinds; S Mittnacht; V Dulic; A Arnold; S I Reed; R A Weinberg
Journal:  Cell       Date:  1992-09-18       Impact factor: 41.582

8.  Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4.

Authors:  J Kato; H Matsushime; S W Hiebert; M E Ewen; C J Sherr
Journal:  Genes Dev       Date:  1993-03       Impact factor: 11.361

9.  Overexpression of E2F1 associated with LOH at RB locus and hyperphosphorylation of RB in non-small cell lung carcinoma.

Authors:  Miwa Akasofu Imai; Yoshio Oda; Makoto Oda; Isao Nakanishi; Ei Kawahara
Journal:  J Cancer Res Clin Oncol       Date:  2004-03-03       Impact factor: 4.553

10.  Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome.

Authors:  Vincent Vuaroqueaux; Patrick Urban; Martin Labuhn; Mauro Delorenzi; Pratyaksha Wirapati; Christopher C Benz; Renata Flury; Holger Dieterich; Frédérique Spyratos; Urs Eppenberger; Serenella Eppenberger-Castori
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

View more
  5 in total

1.  The Evolutionarily Conserved C-terminal Domains in the Mammalian Retinoblastoma Tumor Suppressor Family Serve as Dual Regulators of Protein Stability and Transcriptional Potency.

Authors:  Satyaki Sengupta; Raj Lingnurkar; Timothy S Carey; Monica Pomaville; Parimal Kar; Michael Feig; Catherine A Wilson; Jason G Knott; David N Arnosti; R William Henry
Journal:  J Biol Chem       Date:  2015-04-22       Impact factor: 5.157

2.  Selective repression of the Drosophila cyclin B promoter by retinoblastoma and E2F proteins.

Authors:  Rima Mouawad; Pamela Himadewi; Dhruva Kadiyala; David N Arnosti
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2020-04-08       Impact factor: 4.490

3.  Diversification of Retinoblastoma Protein Function Associated with Cis and Trans Adaptations.

Authors:  Rima Mouawad; Jaideep Prasad; Dominic Thorley; Pamela Himadewi; Dhruva Kadiyala; Nathan Wilson; Philipp Kapranov; David N Arnosti
Journal:  Mol Biol Evol       Date:  2019-12-01       Impact factor: 16.240

4.  Role of Drosophila retinoblastoma protein instability element in cell growth and proliferation.

Authors:  Jared S Elenbaas; Rima Mouawad; R William Henry; David N Arnosti; Sandhya Payankaulam
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

5.  Ubiquitination of retinoblastoma family protein 1 potentiates gene-specific repression function.

Authors:  Nitin Raj; Liang Zhang; Yiliang Wei; David N Arnosti; R William Henry
Journal:  J Biol Chem       Date:  2012-10-18       Impact factor: 5.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.